This phase 1a, multicentre, open-label, non-randomized trial (OVM-200-100) aimed to evaluate the safety, tolerability, immunogenicity, and tumour response of OVM-200, a recombinant overlapping peptides (ROPs)-based therapeutic vaccine derived from survivin, an inhibitor of apoptosis protein highly expressed in various cancers. The gene discussed is BIRC5; the disease is cancer.